Pipeline
We are advancing a robust pipeline to address significant unmet medical needs across three key areas: mitigating cancer treatment toxicities associated to chemo and radiotherapy improving women’s health, with a focus on menopause and breast cancer survivors; and preventing and treating human microbiome dysbiosis, particularly in conditions involving host-immune system alterations.
Our clinical research is driven by a commitment to develop safe and effective that enhance patient outcomes and overall quality of life.
| MUCOSA INNOVATIONS R&D pipeline | INDICATION | DISCOVERY | PRECLINICAL | CLINICAL | |||
| Phase 2 | Phase 3 | ||||||
| Protocol under Development | Safety – Eficacy | On-Going Trials | |||||
|
Cancer Treatment Toxicity (Chemo & Radiotherapy)
|
Prevention & Treatment of orogastrointestinal mucositis
|
|
|
|
|
|
|
|
Women’s Health
|
Menopause (GSM) |
|
|
|
|
|
|
| Breast Cancer Survivors (VVA) |
|
|
|
|
|
||
| Prepuberal vulvitis |
|
|
|
||||
|
Microbiome Dysbiosis
|
Advanced Microbiome Care in Oral Health |
|
|
|
|
|
|
| Oral mucosa Dysbiosis-driven inflammation in chronic inflammatory diseases |
|
|
|
|
|
||
| Oral Dysbiosis -driven inflamation in OSA |
|
|
|
||||
| Oral Dysbiosis & IBD/IBS |
|
|
|
||||
| Obesogenic cytokines cut down in overweight patients |
|
|
|
||||
| Improvement of Skin Barrier Function in Atopic Dermatitis |
|
|
|
||||
| MUCOSA INNOVATIONS R&D pipeline |
INDICATION | DISCOVERY | PRECLINICAL | CLINICAL | ||
|---|---|---|---|---|---|---|
| Protocol under Development |
Phase 2 Safety – Efficacy |
Phase 3 On-Going Trials |
||||
| Cancer Treatment Toxicity (Chemo & Radiotherapy) |
Prevention & Treatment of orogastrointestinal mucositis | |||||
| Women’s Health | Menopause (GSM) | |||||
| Breast Cancer Survivors (VVA) | ||||||
| Prepubescent Pediatric vulvitis | ||||||
| Microbiome Dysbiosis | Advanced Microbiome Care in Oral Health | |||||
| Oral diseases Dysbiosis-driven inflammation in chronic inflammatory diseaser | ||||||
| Oral Dysbiosis -driven inflammation in OSA | ||||||
| Oral Dysbiosis & IBD/IBS | ||||||
| Obesogenic cytokines cut down in overweight patients | ||||||
| Improvement of Skin Barrier Function in Atopic Dermatitis, Psoriasis and Antianging | ||||||
| MUCOSA INNOVATIONS R&D PIPELINE |
INDICATION | DISCOVERY | PRECLINICAL | CLINICAL | ||
|---|---|---|---|---|---|---|
| PROTOCOL UNDER DEVELOPMENT |
PHASE 2 SAFETY – EFFICACY |
PHASE 3 ON-GOING TRIALS |
||||
| Cancer Treatment Toxicity (Chemo & Radiotherapy) |
Prevention & Treatment of orogastrointestinal mucositis | |||||
| Women’s Health | Menopause (GSM) | |||||
| Breast Cancer Survivors (VVA) | ||||||
| Prepubescent Pediatric vulvitis | ||||||
| Microbiome Dysbiosis | Advanced Microbiome Care in Oral Health | |||||
| Oral diseases Dysbiosis-driven inflammation in chronic inflammatory diseaser | ||||||
| Oral Dysbiosis -driven inflammation in OSA | ||||||
| Oral Dysbiosis & IBD/IBS | ||||||
| Obesogenic cytokines cut down in overweight patients | ||||||
| Improvement of Skin Barrier Function in Atopic Dermatitis, Psoriasis and Antianging | ||||||